MICHAEL RUSSO: Open Payments
NPI 1194887125 · MARRERO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,214 in 62 payments from 18 companies in 2025. Trend: 2023 $1,517 · 2024 $1,340 · 2025 $1,214
Food & beverage: $1,213Education: $1
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $212 |
| GlaxoSmithKline, LLC. | 8 | $169 |
| ABBVIE INC. | 11 | $157 |
| Vanda Pharmaceuticals Inc. | 7 | $145 |
| Corcept Therapeutics | 5 | $111 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $81 |
| Novo Nordisk Inc | 3 | $57 |
| Lundbeck LLC | 2 | $42 |
| Indivior Inc. | 1 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
Products named: TRELEGY ELLIPTA, BREZTRI, Korlym, VRAYLAR, FANAPT, FARXIGA, Kerendia, REXULTI.
Industry payments across LA — which companies pay providers there.
